Source disclosure: March 06, 2026, 09:20 JST
Published by Pulse News Wire: March 06, 2026, 09:23 JST
SUMITOMO CHEMICAL COMPANY,LIMITED [4005.T]
TOKYO, Mar 06 (Pulse News Wire) – Sumitomo Chemical Company,limited (4005.T) announced its subsidiary, Sumitomo Pharma Co., Ltd., and RACTHERA Corporation received conditional and time-limited approval for their non-self induced pluripotent stem cell-derived product, Amsherpri, in Japan on March 06, 2026. This marks the world's first approval for an iPSC-based regenerative medicine.
Amsherpri is expected to become a blockbuster drug surpassing ¥1 trillion in sales by the 2030s. It targets patients with Parkinson's disease who do not respond adequately to existing treatments such as levodopa-containing medications. The product was developed based on results from a Phase I/II clinical trial conducted at Kyoto University Hospital.
Sumitomo Pharma will handle manufacturing through S-RACMO Corporation, while marketing responsibilities fall to Sumitomo Pharma itself. Conditions tied to the approval require post-marketing clinical trials and performance evaluations within a set timeframe. This breakthrough represents a significant milestone in Sumitomo Chemical's long-term strategy to expand into regenerative and cellular medicines as key growth areas.
The company plans to continue advancing innovative treatment options for patients suffering from Parkinson's disease.
AI-translated content. 🔴 Confidence: Review recommended See terms • Original filing